| Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease J Liu, SJ Blake, MCR Yong, H Harjunpää, SF Ngiow, K Takeda, A Young, ... Cancer discovery 6 (12), 1382-1399, 2016 | 789 | 2016 |
| Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells Y Gao, F Souza-Fonseca-Guimaraes, T Bald, SS Ng, A Young, SF Ngiow, ... Nature immunology 18 (9), 1004-1015, 2017 | 603 | 2017 |
| Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses A Young, SF Ngiow, DS Barkauskas, E Sult, C Hay, SJ Blake, Q Huang, ... Cancer Cell 30 (3), 391-403, 2016 | 386 | 2016 |
| Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy SJ Blake, WC Dougall, JJ Miles, MWL Teng, MJ Smyth Clinical Cancer Research 22 (21), 5183-5188, 2016 | 257 | 2016 |
| Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy SJ Blake, K Stannard, J Liu, S Allen, MCR Yong, D Mittal, AR Aguilera, ... Cancer discovery 6 (4), 446-459, 2016 | 239 | 2016 |
| Early-Life Antibiotic-Driven Dysbiosis Leads to Dysregulated Vaccine Immune Responses in Mice MA Lynn, DJ Tumes, JM Choo, A Sribnaia, SJ Blake, LEX Leong, ... Cell host & microbe 23 (5), 653-660. e5, 2018 | 185 | 2018 |
| Flow Cytometric Analysis of Cell Division by Dilution of CFSE and Related Dyes AB Lyons, SJ Blake, KV Doherty Current protocols in cytometry, 9.11. 1-9.11. 12, 2013 | 183 | 2013 |
| The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro S Blake, TP Hughes, G Mayrhofer, AB Lyons Clinical immunology 127 (3), 330-339, 2008 | 133 | 2008 |
| CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function D Mittal, A Lepletier, J Madore, AR Aguilera, K Stannard, SJ Blake, ... Cancer immunology research 7 (4), 559-571, 2019 | 108 | 2019 |
| Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer J Liu, SJ Blake, H Harjunpää, KA Fairfax, MCR Yong, S Allen, HE Kohrt, ... Cancer research 76 (18), 5288-5301, 2016 | 104 | 2016 |
| Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell–rich tumor SF Ngiow, A Young, SJ Blake, GR Hill, H Yagita, MWL Teng, AJ Korman, ... Cancer research 76 (21), 6266-6277, 2016 | 100 | 2016 |
| Dasatinib suppresses in vitro natural killer cell cytotoxicity SJ Blake, A Bruce Lyons, CK Fraser, JD Hayball, TP Hughes Blood, The Journal of the American Society of Hematology 111 (8), 4415-4416, 2008 | 93 | 2008 |
| Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers LF Pittet, NL Messina, F Orsini, CL Moore, V Abruzzo, S Barry, R Bonnici, ... New England Journal of Medicine 388 (17), 1582-1596, 2023 | 91 | 2023 |
| Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies J Liu, SJ Blake, MJ Smyth, MWL Teng Clinical & translational immunology 3 (8), e22, 2014 | 83 | 2014 |
| Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo CK Fraser, SJ Blake, KR Diener, AB Lyons, MP Brown, TP Hughes, ... Experimental hematology 37 (2), 256-265, 2009 | 77 | 2009 |
| Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease L Le Texier, KE Lineburg, B Cao, C McDonald-Hyman, ... JCI Insight 1 (15), 2016 | 66 | 2016 |
| siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo N Khairuddin, MP Gantier, SJ Blake, SY Wu, MA Behlke, BRG Williams, ... Immunology and cell biology 90 (2), 187-196, 2012 | 61 | 2012 |
| Role of IL-17 and IL-22 in autoimmunity and cancer SJ Blake, MWL Teng Actas dermo-sifiliograficas 105, 41-50, 2014 | 59 | 2014 |
| Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment SJP Blake, ALH Ching, TJ Kenna, R Galea, J Large, H Yagita, RJ Steptoe PloS one 10 (3), e0119483, 2015 | 51 | 2015 |
| Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis H Harjunpää, SJ Blake, E Ahern, S Allen, J Liu, J Yan, V Lutzky, K Takeda, ... OncoImmunology 7 (7), e1445949, 2018 | 48 | 2018 |
